GlobeNewswire Inc.··Not SpecifiedMaze Therapeutics Raises $150M to Fund Late-Stage Drug Pipeline Through 2029
Maze Therapeutics prices $150M offering at $23.50/share, securing funding through 2029 for kidney disease and PKU programs.
MAZEclinical developmentcapital raise